Building or backing a longevity company? See who actually pays, and for what

Updated October 202670+ pagesPDF

Longevity Business Models
Cover of NewMarketPitch's Longevity Business Models report, 2026 edition
Is Neko Health, the body-scan startup, really worth $7 billion? Not on sales, mostly on promise. Neko sold ~$16M of body scans in 2025 and lost ~$70M. At ~$7B, it is valued at 430 times its sales. Chart from NewMarketPitch's Longevity report.
What does a longevity checkup cost, and what do you get? From free to $23,500 a year. Blood-test memberships cost $199 to $365 a year, and one whole-body MRI as much as ~7 years of Function. Chart from NewMarketPitch's Longevity report.
How expensive are longevity companies, measured by sales? Very, in private rounds. Neko Health is valued at ~430 times its 2025 sales. The GLP-1 giants, Novo and Lilly, trade at 3.5 and 14 times. Chart from NewMarketPitch's Longevity report.
Are longevity startups tiny next to GLP-1 maker Eli Lilly? Yes, tiny. Eli Lilly is worth ~52 times the seven most valued longevity startups put together. Its yearly sales alone are ~4 times their value. Chart from NewMarketPitch's Longevity report.
Who is fighting on which front of the longevity market? Startups fight on almost every front, from cell reprogramming to body scans. Drug giants mostly fight on one, weight loss, and Loyal is alone on dog lifespan. Chart from NewMarketPitch's Longevity report.
Who is fighting whom in the longevity market today? Function leads blood tests, Life Biosciences reprogramming in people, Lilly GLP-1 sales. Body scans are split, and Loyal is alone on dog lifespan. Chart from NewMarketPitch's Longevity report.
Do full-body scans find far more scares than cancers? Yes. In the latest review of 17 studies, 78 of 100 people scanned had a finding and ~15 needed more tests for something that was not cancer. ~1 had a cancer. Chart from NewMarketPitch's Longevity report.
How many drugs are approved to treat aging itself? None, the FDA does not treat aging as a disease. Yet billions went into the hunt, from Altos Labs’ $3B to $1.65B for aging-drug startups recently. Chart from NewMarketPitch's Longevity report.
Are clinics and supplements selling longevity without proof? Yes. No longevity clinic or supplement has shown in a trial that it adds healthy years. GLP-1s cut deaths, but only in people with heart disease. Chart from NewMarketPitch's Longevity report.

70+ pages in the full report

Swipe· 70+ pages in the report

Inside the report

  • Which business models are winning
  • Who pays, and for what
  • Who makes money, who burns cash
  • Where revenue could come from
  • Who are the top companies today
  • Who’s ahead, and who’s falling behind
  • What are their valuations
  • Who’s getting funded, and by whom
  • What are the biggest unsolved problems
  • What has changed in the last 12 months
  • Where are the biggest opportunities
  • Who are the likely future winners
$99$79one-time payment
Get the report

Verified data with sourcesUpdated in October 2026